This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Treatment With Copper in Patients With Mild Alzheimer´s Dementia

This study has been completed.
Sponsor:
Collaborator:
University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany
Information provided by:
University Hospital, Saarland
ClinicalTrials.gov Identifier:
NCT00608946
First received: January 23, 2008
Last updated: February 5, 2008
Last verified: January 2008
  Purpose
The efficacy of 8 mg of copper daily regarding cognitive function, content of beta amyloid protein in the CSF and volumetric changes in the brain will be examined in a first double-blind, placebo-controlled human clinical trial conducted in 70 patients with mild Alzheimer´s dementia.

Condition Intervention Phase
Alzheimer´s Disease Dietary Supplement: copper Dietary Supplement: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by University Hospital, Saarland:

Primary Outcome Measures:
  • change of cognitive function, measured by ADAS-cog [ Time Frame: one year ]

Secondary Outcome Measures:
  • change of beta amyloid in the CSF and volumetric changes in the brain [ Time Frame: one year ]

Enrollment: 68
Study Start Date: March 2004
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
efficacy of the intake of 8 mg of copper daily per os for one year under observation of cognitive status unless unacceptable side effects appear
Dietary Supplement: copper
intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
Placebo Comparator: 2
placebo
Dietary Supplement: placebo
placebo

  Eligibility

Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • male or female patients
  • between 50 and 80 years
  • criteria of mild dementia
  • probable Alzheimer´s dementia according to NINCDS-ADRDA criteria
  • given written informed consent
  • having a relative who can fill out questionnaire; caregiver consent
  • free of serious and unstable somatic illness

Exclusion Criteria:

  • unable to give informed consent
  • unable to take cholinesterase inhibitors
  • unapproved medication
  • moderate to severe Alzheimer´s disease
  • dementia of other etiology
  • history of alcohol, drug or medication abuse
  • other psychiatric disorder, e. g. schizophrenia
  • known copper and zinc storage disease
  • known copper and zinc intolerance
  • vegans
  • known severe allergies or intolerances
  • insufficient knowledge of the German language
  • female patients of childbearing potential, pregnant or nursing patients
  • participation in a clinical trial within the past 30 days before onset of this study
  • severe somatic diseases and high mortality rate AST, ALT, GGT, GLDH, AP or bilirubin being a two-fold above the normal range
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00608946

Sponsors and Collaborators
University Hospital, Saarland
University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany
Investigators
Principal Investigator: Frank G Pajonk, M.D., lecturer Dept. of Psychiatry and Psychotherapy, The Saarland University Hospital
  More Information

Additional Information:
Publications:
Responsible Party: Frank-Gerald Pajonk, M.D., Lecturer, Dept. of Psychiatry and Psychotherapy, The Saarland University Hospital
ClinicalTrials.gov Identifier: NCT00608946     History of Changes
Other Study ID Numbers: UKS-PSY-DEM-01
Study First Received: January 23, 2008
Last Updated: February 5, 2008

Keywords provided by University Hospital, Saarland:
efficacy of treatment with copper in patients with mild Alzheimer´s disease
cognitive status over time
CSF and volumetric data over time (1 year)

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Copper
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 18, 2017